Isolde vs Emanuel’s Target Market
Isolde from Siiquent targets the clinical diagnostics market such as hospitals and large diagnostic laboratories conducting gene-based medical testing—it operates in a heavily regulated, healthcare-focused environment. Siiquent has the “razor-blade” business model, meaning the company mostly profits from recurring revenue, not one-time costs.Specifically, they earn profit from ongoing sales of biological and chemical compounds, test kits, and reagents (Bertini and Tavassoli, 2015). To meet consumers’ needs, they provide free regulatory guidance and extensive maintenance service.
Emanuel from Teomik, in contrast, targets the research and academic market, operating in a scientific research environment with far fewer regulatory constraints and focus on innovation and performance over cost. Its revenue model focuses on high-margin equipment sales, leveraging patented equipment to sell specialized instruments at high prices (Bertini and Tavassoli, 2015). Unlike Siiquent, consumables are a secondary, low-margin source of income. In short, Teomik’s value lies in its technology and expert scientific support, rather than price competitiveness.
Imposing a Single Structure vs a Flexible Structure
Imposing a single revenue structure would simplify Scherr’s overall strategy, align company incentives across teams and make it easier for sales teams to deliver a consistent value prop to customers. It would streamline internal operations, reduce confusion, and make resource allocation more predictable. However, this approach could also abandon the distinct advantages that made each business unit successful. For instance, eliminating Siiquent’s pay-per-test model might frustrate customers that rely on its cost-saving flexibility, while abandoning Teomik’s high-end pricing could undermine its brand reputation and margins.
Allowing a flexible, dual-structure approach, on the other hand, would preserve the strengths of both models and allow each to continue serving its respective market effectively. It would allow the company to respond to different customer needs, encourage innovation, and leverage the company’s existing expertise in both regulated and unregulated environments. The downside, however, is that flexibility can quickly turn into strategic ambiguity—causing internal competition, unclear performance metrics, and inconsistent customer experiences (which Peter is most concerned about).
Mediating the Merge
If I were the PM mediating this merger, I would begin by focusing on customer segmentation and user needs rather than forcing structural uniformity. I’d start by (1) identifying the core pain points and decision drivers of each segment (clinical vs. research market), (2) overlaps where shared infrastructure or service models could exist and (3) conflicts, such as pricing expectations or sales incentive differences, that must be intentionally managed.
Next, I would propose a hybrid model with clear segmentation, where both revenue models coexist under a unified brand and shared service layer (e.g. distinct pricing and sales strategies for each customer group, shared backend operations, unified data and customer success teams). Finally, I’d establish governance mechanisms such as clear ownership of different divisions and KPIs to maintain flexibility without losing strategic focus.
